Gene Therapy Developed for ALS Treatment: New Biotech Company Neuralgene Enters Evaluation Phase

Patent-pending PRCN-829 delivers multiple genes, including Factor H, neural growth factors and regulators of TDP-43 to treat neurodegenerative disease ALS /PRNewswire/ -- Startup biotechnology company Neuralgene has announced that it will begin animal studies in May to evaluate the efficacy of PRCN-829, its new gene therapy agent for the treatment ... (more)

http://www.prnewswire.com/news-releases/gene-therapy-developed-for-als-treatment-new-biotech-company-neuralgene-enters-evaluation-phase-202686101.html